

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

NCI-H2347

RRID:CVCL_1550

Type: Cell Line

Proper Citation

RRID:CVCL_1550

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1550

Proper Citation: RRID:CVCL_1550

Description: Cell line NCI-H2347 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:9559342](#), [PMID:10987304](#), [PMID:11030152](#), [PMID:11314036](#), [PMID:12068308](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24700732](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2347

Synonyms: H2347, H-2347, NCIH2347

Cross References: BTO:BTO_0005293, CLO:CLO_0008074, EFO:EFO_0002287, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5942, BioSample:SAMN03472999, BioSample:SAMN10987629, cancercellines:CVCL_1550,

CCRID:3101HUMSCSP5002, Cell_Model_Passport:SIDM00726, ChEMBL-Cells:ChEMBL3308386, ChEMBL-Targets:ChEMBL1075538, CLS:305139, Cosmic:687820, Cosmic:877253, Cosmic:903620, Cosmic:914950, Cosmic:1146907, Cosmic:1239893, Cosmic:1925843, Cosmic:2125248, Cosmic:2776270, Cosmic-CLP:687820, DepMap:ACH-000875, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687820, GEO:GSM62332, GEO:GSM108841, GEO:GSM108842, GEO:GSM253354, GEO:GSM303896, GEO:GSM337707, GEO:GSM434254, GEO:GSM513963, GEO:GSM514348, GEO:GSM784201, GEO:GSM794366, GEO:GSM817104, GEO:GSM827514, GEO:GSM844644, GEO:GSM887420, GEO:GSM888499, GEO:GSM1374737, GEO:GSM1670231, IARC_TP53:21563, IARC_TP53:28451, IGRhCellID:NCIH2347, LiGeA:CCLE_615, LINCS_LDP:LCL-1620, PharmacDB:NCIH2347_1087_2019, PRIDE:PXD030304, Progenetix:CVCL_1550, PubChem_Cell_line:CVCL_1550, Wikidata:Q54907966

ID: CVCL_1550

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260829T234732+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2347.

No alerts have been found for NCI-H2347.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. *Molecular cancer therapeutics*, 25(4), 599.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular cell*, 85(7), 1311.

Ray P, et al. (2025) SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy. *Molecular cancer research : MCR*, 23(6), 530.

Horie M, et al. (2024) Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. *Molecular oncology*, 18(1), 21.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.

Zhao K, et al. (2021) Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. *Molecular cancer research : MCR*, 19(9), 1571.

Inoue Y, et al. (2021) Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. *eLife*, 10.

Kang YP, et al. (2021) Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis. *Cell metabolism*, 33(1), 174.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. *BMC cancer*, 19(1), 1203.

Yin N, et al. (2019) Protein Kinase C?? and Wnt/??-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. *Cancer cell*, 36(2), 156.

Kang YP, et al. (2019) Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. *eLife*, 8.

Watanabe H, et al. (2013) Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. *Genes & development*, 27(2), 197.